Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 12:31 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 5,448 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Control Subjects Clear all
Completed Phase 2 Interventional Results available

Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease

NCT02188160
View directory record Official record
Conditions
Dry Eye Syndromes, Keratoconjunctivitis Sicca
Interventions
KPI-121, Placebo
Drug
Lead sponsor
Kala Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
11
States / cities
Artesia, California • Mission Hills, California • Rancho Cordova, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2021 · Synced Oct 20, 2026, 12:31 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of EDP-938 in Healthy Subjects

NCT03384823
View directory record Official record
Conditions
RSV Infection
Interventions
EDP-938, Placebo
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 10, 2018 · Synced Oct 20, 2026, 12:31 AM EDT
Terminated Phase 3 Interventional Results available

Zephyrus I: Evaluation of Efficacy and Safety of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)

NCT03955146
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Pamrevlumab, Placebo
Drug
Lead sponsor
Kyntra Bio
Industry
Eligibility
40 Years to 85 Years
Enrollment
393 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
60
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 50 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 20, 2026, 12:31 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, Pharmacokinetics And Measurement Of Whole Blood Activity (WBA) Of PNU-100480 After Multiple Oral Doses In Healthy Adult Volunteers

NCT00990990
View directory record Official record
Conditions
Tuberculosis
Interventions
PNU-100480, Placebo, Linezolid
Drug
Lead sponsor
Sequella, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 28, 2013 · Synced Oct 20, 2026, 12:31 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Randomized, Double-blind, Placebo-controlled, Sequential Ascending, Single-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2212 in Healthy Subjects

NCT01221259
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
E2212, placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated May 22, 2013 · Synced Oct 20, 2026, 12:31 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety and Tolerability of Single Doses of AZD4076 in Healthy Male Subjects

NCT02612662
View directory record Official record
Conditions
Non-alcoholic Steatohepatitis (NASH)
Interventions
AZD4076, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2025
U.S. locations
1
States / cities
Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 20, 2026, 12:31 AM EDT
Completed Phase 3 Interventional Results available

Study to Assess the Long Term Safety and Tolerability of ACT-541468 (Daridorexant) in Adult and Elderly Subjects Suffering From Difficulties to Sleep

NCT03679884
View directory record Official record
Conditions
Insomnia Disorder
Interventions
Daridorexant 10 mg, Daridorexant 25 mg, Daridorexant 50 mg, Placebo
Drug
Lead sponsor
Idorsia Pharmaceuticals Ltd.
Industry
Eligibility
18 Years and older
Enrollment
804 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
53
States / cities
Birmingham, Alabama • Glendale, Arizona • Tucson, Arizona + 47 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Oct 20, 2026, 12:31 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Healthy Volunteer And Patient Study To Assess The Safety, Tolerability And Pharmacokinetics Of GSK1265744

NCT00659191
View directory record Official record
Conditions
HIV Infection
Interventions
GSK1265744
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
5
States / cities
Fort Lauderdale, Florida • Orlando, Florida • Charlotte, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2010 · Synced Oct 20, 2026, 12:31 AM EDT
Completed Phase 1 Interventional

Single-Dose Study Of PF-04603629 In Type 2 Diabetic Subjects

NCT00638313
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Placebo, PF-04603629
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
2
States / cities
Phoenix, Arizona • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 31, 2009 · Synced Oct 20, 2026, 12:31 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis

NCT04620213
View directory record Official record
Conditions
Mydriasis, Dilation
Interventions
Phentolamine Ophthalmic Solution 0.75%, Phentolamine Ophthalmic Solution Vehicle (Placebo)
Drug · Other
Lead sponsor
Opus Genetics, Inc
Industry
Eligibility
12 Years and older
Enrollment
185 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
12
States / cities
Newport Beach, California • San Diego, California • Longwood, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2023 · Synced Oct 20, 2026, 12:31 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate Safety, Tolerability, and Pharmacokinetics of JNJ-56136379 in Healthy Japanese Adult Participants

NCT02933580
View directory record Official record
Conditions
Healthy
Interventions
JNJ-56136379, Placebo
Drug · Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
20 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Mar 16, 2018 · Synced Oct 20, 2026, 12:31 AM EDT
Completed Phase 3 Interventional

A Study of Torcetrapib/Atorvastatin vs Atorvastatin Alone or Placebo in Patients With High Cholesterol

NCT00138762
View directory record Official record
Conditions
Hyperlipidemia
Interventions
torcetrapib/atorvastatin, atorvastatin, placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
3,800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
96
States / cities
Mobile, Alabama • Mesa, Arizona • Oro Valley, Arizona + 93 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2012 · Synced Oct 20, 2026, 12:31 AM EDT
Completed Phase 2 Interventional

A Study of Anagrelide Controlled Release (GALE-401) in Patients With High Platelet Counts Due to Bone Marrow Disorders

NCT02125318
View directory record Official record
Conditions
Thrombocytosis, Myeloproliferative Neoplasms
Interventions
Anagrelide CR
Drug
Lead sponsor
Galena Biopharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
11
States / cities
Burbank, California • Encinitas, California • Escondido, California + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2017 · Synced Oct 20, 2026, 12:31 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Phase III Study to Demonstrate the Safety and Efficacy of DWP-450 to Treat Glabellar Lines - EV001

NCT02334423
View directory record Official record
Conditions
Glabellar Frown Lines
Interventions
Botulinum toxin, Type A, 0.9% sterile, unpreserved saline
Biological · Other
Lead sponsor
Evolus, Inc.
Industry
Eligibility
18 Years and older
Enrollment
330 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Boca Raton, Florida
Source: ClinicalTrials.gov public record
Updated Mar 27, 2019 · Synced Oct 20, 2026, 12:31 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Safety, Tolerability and Pharmacokinetic Study of ABT-102 in Healthy Subjects

NCT00854659
View directory record Official record
Conditions
Healthy Volunteers
Interventions
ABT-102, Placebo
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2009
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 2, 2010 · Synced Oct 20, 2026, 12:31 AM EDT
Completed Phase 2 Interventional

A Study of the Novel Drug Dimebon in Patients With Huntington's Disease

NCT00497159
View directory record Official record
Conditions
Huntington's Disease
Interventions
Placebo, Dimebon
Other · Drug
Lead sponsor
Medivation, Inc.
Industry
Eligibility
29 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jun 8, 2015 · Synced Oct 20, 2026, 12:31 AM EDT
Completed Phase 2 Interventional Results available

A Safety and Efficacy Study of JNJ-42165279 in Participants With Social Anxiety Disorder

NCT02432703
View directory record Official record
Conditions
Phobic Disorders
Interventions
JNJ-42165279, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
13
States / cities
La Jolla, California • Hartford, Connecticut • Orlando, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 20, 2026, 12:31 AM EDT
Completed Phase 2 Interventional Results available

Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-centre, Dose Ranging Study to Evaluate the Efficacy and Safety of Losmapimod Tablets Administered Twice Daily Compared With Placebo for 24 Weeks in Adult Subjects With Chronic Obstructive Pulmonary Disease (COPD).

NCT01218126
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
losmapimod, placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
604 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
8
States / cities
Birmingham, Alabama • Torrance, California • Rochester, Minnesota + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2018 · Synced Oct 20, 2026, 12:31 AM EDT
Completed Phase 1 Interventional

Study of TAK-925 in Participants With Obstructive Sleep Apnea (OSA) Who Are Experiencing Excessive Daytime Sleepiness (EDS) Despite Adequate Use of Continuous Positive Airway Pressure (CPAP)

NCT04091425
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
TAK-925, Placebo
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 67 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
18
States / cities
Alabaster, Alabama • Glendale, Arizona • Little Rock, Arkansas + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2020 · Synced Oct 20, 2026, 12:31 AM EDT
Completed Phase 2 Interventional

Induction and Maintenance Study of BMS-936557 Patients With Moderate to Severe Ulcerative Colitis

NCT01294410
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
Placebo, Anti-IP-10 Antibody
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
23
States / cities
La Jolla, California • Santa Monica, California • Wheat Ridge, Colorado + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2015 · Synced Oct 20, 2026, 12:31 AM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Evaluating Intra-articular Injection of Axolotl Ambient Compared to Saline in Subjects With Ankle Osteoarthritis

NCT05092646
View directory record Official record
Conditions
Ankle Osteoarthritis
Interventions
Axolotl Ambient, "Drug/Placebo: 0.9% Normal Saline"
Biological · Drug
Lead sponsor
Axolotl Biologix
Industry
Eligibility
18 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
3
States / cities
Boise, Idaho • Shreveport, Louisiana • Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 20, 2026, 12:31 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis

NCT03985943
View directory record Official record
Conditions
Moderate-to-Severe Atopic Dermatitis
Interventions
Placebo, Nemolizumab
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
12 Years and older
Enrollment
941 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
57
States / cities
North Little Rock, Arkansas • Cerritos, California • Fountain Valley, California + 48 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2024 · Synced Oct 20, 2026, 12:31 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Escalating Multiple Doses of TAK-831 in Healthy Participants

NCT03224325
View directory record Official record
Conditions
Healthy
Interventions
TAK-831 Tablet T2, Placebo, TAK-831 Suspension
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
18 Years to 55 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Jun 14, 2021 · Synced Oct 20, 2026, 12:31 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Safety Study of ALRN-5281 in Healthy Subjects

NCT01775358
View directory record Official record
Conditions
Growth Hormone Deficiency
Interventions
ALRN-5281 0.015 mg/kg, ALRN-5281 0.05 mg/kg, ALRN-5281 0.15 mg/kg, Placebo 0.015 mg/kg, Placebo 0.05mg/kg, Placebo 0.15mg/kg
Drug
Lead sponsor
Aileron Therapeutics, Inc.
Industry
Eligibility
20 Years to 50 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated May 30, 2013 · Synced Oct 20, 2026, 12:31 AM EDT